Gotowe bibliografie tematyczne / Radiation-induced lymphopenia

Spis treści

Artykuły w czasopismach
Rozprawy doktorskie
Streszczenia konferencji

Gotowa bibliografia na temat „Radiation-induced lymphopenia”

Autor: Grafiati

Data publikacji: 26 października 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Radiation-induced lymphopenia”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Radiation-induced lymphopenia"

Wang, Xin, Peiliang Wang, Zongxing Zhao, Qingfeng Mao, Jinming Yu i Minghuan Li. "A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy". Therapeutic Advances in Medical Oncology 12 (styczeń 2020): 175883592092682. http://dx.doi.org/10.1177/1758835920926822.

Pełny tekst źródła

Streszczenie:

Radiotherapy is a frequently utilized therapeutic modality in the treatment of esophageal cancer (EC). Even though extensive studies are carried out in radiotherapy for EC, the design of the clinical target volume and the radiation dose is not satisfactorily uniform. Radiotherapy acts as a double-edged sword on the immune system; it has both an immunostimulatory effect and an immunosuppressive effect. Radiation-induced lymphopenia and its potential association with tumor control and survival outcomes remain to be understood. The advent of immunotherapy has renewed the focus on preserving a pool of functioning lymphocytes in the circulation. In this review, we summarize the potential impact mechanisms of radiotherapy on peripheral blood lymphocytes and the prognostic role of radiation-induced lymphopenia in patients with EC. We also propose the concept of organs-at-risk of lymphopenia and discuss potential strategies to mitigate its effects on patients with EC. From an immunological perspective, we put forward the hypothesis that optimizing radiation modalities, radiation target volume schemes, and radiation doses could help to reduce radiation-induced lymphopenia risks and maximize the immunomodulatory role of radiotherapy. An optimized radiotherapy plan may further enhance the feasibility and effectiveness of combining immunotherapy with radiotherapy for EC.

Style APA, Harvard, Vancouver, ISO itp.

Sashidharan, Srijith, Azadeh Abravan, Peter Sitch, Cy Howells, Ed Smith i Shermaine Pan. "Radiation-induced lymphopenia with proton beam therapy (PBT)". Clinical Oncology 34 (wrzesień 2022): e2-e3. http://dx.doi.org/10.1016/j.clon.2022.08.009.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Ballal, Suhas, Shruti Chandak, Karan Ram Lal Gupta i Geetika M. Patel. "A systematic review of the management and implications of radiation-induced lymphopenia and the predictive rate of radiomic-based approaches in lung cancer". Multidisciplinary Reviews 6 (29.01.2024): 2023ss008. http://dx.doi.org/10.31893/multirev.2023ss008.

Pełny tekst źródła

Streszczenie:

Radiation therapy remains a crucial treatment option for lung cancer, but radiation-induced lymphopenia can impact treatment results and patient well-being. Radiomics-based techniques have made it easier to predict therapy response and patient outcomes by extracting and analyzing quantitative imaging characteristics. This review examines radiation-induced lymphopenia management and its consequences while evaluating the predictive capabilities of radiomics-based approaches in the lung cancer context. A systematic review was undertaken using Scinapse, Scholar and PubMed, with 1247 papers chosen based on predefined criterion for inclusion and exclusion. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines declaration, 15 peer-reviewed studies published between 2019 and 2021 were included in the review after removing duplicates. The search technique retrieved 491 studies from PubMed, 540 from Scinapse and 250 from Google Scholar. In this quantitative statistic, we provided categorical data as the interquartile range (IQR) for constants and fractions. Then, we reviewed papers that examined techniques for managing radiation-induced lymphopenia and its implications for treatment results. These techniques were correlated with possible improvements in patient outcomes and a decrease in the degree of lymph node dysfunction. An examination of forest plots was carried out to assess the prediction efficiency of radiomics-based techniques in forecasting lung cancer patient survival and to summarize therapy regimens for radiation-induced lymphoma. The Radiomics Quality Score (RQS) was used as a quantitative tool to assess the consequences of radiation-induced lymphopenia. Patients having radiation-related lymph node dysfunction have an elevated risk of developing lung tambours and dying from it. Especially in people who have additional risk factors, minimizing the lung and heart dosage could reduce lymphopenia and perhaps enhance the course of therapy for these patients.

Style APA, Harvard, Vancouver, ISO itp.

Sengupta, Sadhak, Jaclyn Marrinan, Caroline Frishman i Prakash Sampath. "Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy". Clinical and Developmental Immunology 2012 (2012): 1–7. http://dx.doi.org/10.1155/2012/831090.

Pełny tekst źródła

Streszczenie:

Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a median survival time of 15 months. The established therapeutic regimen includes a tripartite therapy of surgical resection followed by radiation and temozolomide (TMZ) chemotherapy, concurrently with radiation and then as an adjuvant. TMZ, a DNA alkylating agent, is the most successful antiglioma drug and has added several months to the life expectancy of malignant glioma patients. However, TMZ is also responsible for inducing lymphopenia and myelosuppression in malignant glioma patients undergoing chemotherapy. Although TMZ-induced lymphopenia has been attributed to facilitate antitumor vaccination studies by inducing passive immune response, in general lymphopenic conditions have been associated with poor immune surveillance leading to opportunistic infections in glioma patients, as well as disrupting active antiglioma immune response by depleting both T and NK cells. Deletion of O6-methylguanine-DNA-methyltransferase (MGMT) activity, a DNA repair enzyme, by temozolomide has been determined to be the cause of lymphopenia. Drug-resistant mutation of the MGMT protein has been shown to render chemoprotection against TMZ. The immune modulating role of TMZ during glioma chemotherapy and possible mechanisms to establish a strong TMZ-resistant immune response have been discussed.

Style APA, Harvard, Vancouver, ISO itp.

Yu, Hao, Fang Chen, Li Yang, Jian-Yue Jin i Feng-Ming Spring Kong. "Potential determinants of radiation-induced lymphocyte decrease and lymphopenia in breast cancer patients by machine learning approaches." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e12567-e12567. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e12567.

Pełny tekst źródła

Streszczenie:

e12567 Background: Radiation-induced lymphopenia accompanied with radiation therapy is associated with inferior clinical outcomes in a wide variety of solid malignancies. This study aimed to examine the potential determines of radiation-induced lymphocyte decrease and radiation-induced lymphopenia in breast cancer patients who underwent radiotherapy. Methods: Patients with breast cancer treated who underwent radiotherapy were enrolled in University of Hong Kong-Shenzhen Hospital (our cohort). Circulating lymphocyte levels were evaluated within 7 days prior to and end of radiation therapy. Feature groups including clinical data, tumor characteristics, radiotherapy dosimetrics, treatment regiments were also collected. We applied machine learning algorithms (Extreme Gradient Boosting, XGboost) to predict the ratio of lymphocyte level after radiotherapy to baseline lymphocyte level and the event of lymphopenia and compared with Lasso regression approaches. Next, we used Shapley additive explanation (SHAP) to explore the directional contribution of each feature for lymphocyte decrease and lymphopenia. For the purpose of model validation and proof-of-concept validation, an independent cohort of patients enrolled in prospective trial was eligible (IP cohort). Results: A total of 589 patients were enrolled in our cohort and 203 patients in IP cohort. XGboost models which trained in our cohort with performances of a mean RMSE: 0.157 and R2: 53.9% for the ratio of lymphocyte levels; a mean accuracy: 0.757 and ROC-AUC: 0.733 for the lymphopenia events, separately. These models can predict the ratio of lymphocyte levels with a mean RMSE: 0.175 and R2: 47%; predict the lymphopenia events with a mean accuracy: 0.739 and ROC-AUC: 0.737 in the totally independent IP cohort. The feature group of dosimetrics had the largest predictive power with RMSE: 0.192, R2: 29.8%, accuracy: 0.678 and ROC-AUC: 0.667; followed by the group of baseline blood cells with predictive power as RMSE: 0.207, R2: 18.9%, accuracy: 0.669 and ROC-AUC: 0.645. Next, by SHAP value analysis, we investigated that integral dose of the total body, V5 dose, mean lung dose and V20 dose of ipsilateral lung/bilateral lungs were in consequence important promote factors for lymphocyte decrease and for the event of lymphopenia, while the features of baseline monocyte, mean heart dose and tumor size played a role of protection at some extend. Conclusions: In this study, we constructed robust XGboost models for predicting the lymphocyte decrease and the event of lymphopenia in breast cancer patients who underwent radiation therapy. We also applied SHAP analysis for revealing the directional contribution of features. These results are important either for the understanding the contributions of dosimetrics on immune response or for the refine of radiation dosimetrics before treatment in future clinical usages.

Style APA, Harvard, Vancouver, ISO itp.

Jin, Jian-Yue, Todd Mereniuk, Anirudh Yalamanchali, Weili Wang, Mitchell Machtay, Feng-Ming (Spring)Kong i Susannah Ellsworth. "A framework for modeling radiation induced lymphopenia in radiotherapy". Radiotherapy and Oncology 144 (marzec 2020): 105–13. http://dx.doi.org/10.1016/j.radonc.2019.11.014.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Gupta, Priti, Min Wang i Steven Lin. "Abstract 1118: Mitigating radiation-induced lymphopenia using interleukin-15: Preclinical rationale for clinical translation". Cancer Research 84, nr 6_Supplement (22.03.2024): 1118. http://dx.doi.org/10.1158/1538-7445.am2024-1118.

Pełny tekst źródła

Streszczenie:

Abstract Background: Radiation therapy is a common treatment for cancer patients, with nearly 50% of them undergoing this procedure. While radiation is effective at targeting tumor cells, it also has the unintended consequence of killing lymphocytes, which are among the most sensitive cells to radiation within the erythroid, myeloid, and lymphoid lineages. This phenomenon is known as radiation-induced lymphopenia (RIL) and is considered a negative prognostic factor in various malignant solid tumors. It occurs severely in over 40% of solid tumor patients who receive radiotherapy. Some previous studies have shown promising results with IL15 therapy in increasing circulating lymphocytes in cancer patients. However, until now, no studies have investigated the impact of IL15 in the context of radiation-induced lymphopenia. Our study aims to investigate whether IL15 can boost lymphocyte numbers and decrease tumor burden following radiation treatment in a mouse model. Methods: To conduct our study, we subcutaneously injected TSA tumor cells into the flank region of mice. Once the tumors reached a palpable size, approximately 50mm3, we divided the mice into four groups: Control (Con), Irradiation (IR), Control with IL15 (Con+IL15), and Irradiation with IL15 (IR+IL15). The irradiated mouse groups received a radiation dose of 2 Gray in the thorax and 1 Gray in the spleen for five consecutive days, simulating the severe radiation-induced lymphopenia observed in cancer patients. After the radiation treatment, the IL15-treated groups received IL15 in combination with recombinant IL15 in a 1:6 ratio weekly. Throughout the experiment, we monitored the circulating lymphocytes and tumor growth. After two weeks following the last radiation dose, we euthanized the mice, collected blood, spleen, and tumor samples, and identified immune cells using flow cytometry. Results: The radiation treatment significantly increased tumor growth while decreasing the number of lymphocytes, including B cells, T cells, and NK cells, in the blood. IL15 administration led to an increase in the number of lymphocytes both in the blood and within the tumor compared to the irradiated group. We observed a trend toward reduced tumor growth in the group that received both IL15 and radiation (IR+IL15) compared to the group that received radiation alone (IR). Conclusion: IL15 effectively boosted the number of lymphocytes in both the bloodstream and tumors, resulting in slower tumor growth in the IL15-treated group compared to the irradiated group. This study is of significant importance as it demonstrates the potential of IL15 to counteract radiation-induced lymphopenia in mice with TSA tumors. Further testing of these findings is currently underway in MC38 tumor-bearing mice, a cell line known to be more radiation-sensitive. Citation Format: Priti Gupta, Min Wang, Steven Lin. Mitigating radiation-induced lymphopenia using interleukin-15: Preclinical rationale for clinical translation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1118.

Style APA, Harvard, Vancouver, ISO itp.

Zhao, Qianqian, Tingting Li, Shisuo Du, Jian He i Zhaochong Zeng. "Shortened Radiation Time Promotes Recovery From Radiation-induced Lymphopenia in Early-Stage Non-small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy". Technology in Cancer Research & Treatment 21 (styczeń 2022): 153303382211122. http://dx.doi.org/10.1177/15330338221112287.

Pełny tekst źródła

Streszczenie:

Background: To evaluate the potential impact of radiation time on radiation-induced lymphopenia (RIL) and subsequently recovery after stereotactic body radiation therapy (SBRT) and to examine the associations between radiation time and with patient outcomes in early-stage non-small cell lung cancer (NSCLC). Methods: Clinical and laboratory records of subjects consisted of 115 patients who had received SBRT for early-stage NSCLC. Clinical and laboratory records were retrospective reviewed to assess the changes in total lymphocyte counts (TLCs) following SBRT. Associations of TLCs kinetics with the clinical and treatment features, and outcomes were analyzed. Results: Most patients (100/115, 86.96%) experienced significantly decreased median TLCs following SBRT (1700 vs 1100 cells/µL; P < .001), and 52 patients (45.21%) met the criteria for lymphopenia. Six months after SBRT, 44 patients (38.26%) had recovered. A negative correlation between TLCs reduction and radiation time was observed ( r = −0.381, P < .001). According to the receiver-operating characteristic curve analysis, the optimal cut-off value for radiation time to was 3950 s to predict lymphocyte count recovery (LR) following RIL was 3950 s ( P < .001). Multivariate analyses demonstrated that radiation time was significantly associated with LR (odds ratio [OR], 0.113; 95% confidence interval [CI], 0.029-0.432; P = .001) but not TLCs reduction ( P = .575). LR within 6 months after SBRT was associated with improved progression-free survival in patients without non-lymphopenia ( P = .034), but had little effect in patients with lymphopenia ( P = .405). Conclusion: A longer radiation time was associated with a lower rate of LR within 6 months after SBRT in patients with early-stage NSCLC. Given the association of severe and persistent RIL with survival in NSCLC, further study of the effect of radiation time on immune status is warranted.

Style APA, Harvard, Vancouver, ISO itp.

Ishida, Naoko, Yukinori Matsuo, Junki Fukuda, Aritoshi Ri, Saori Tatsuno, Takuya Uehara, Masahiro Inada i in. "Radiation-Induced Lymphopenia and Its Impact on Survival in Patients with Brain Metastasis". Current Oncology 31, nr 8 (9.08.2024): 4559–67. http://dx.doi.org/10.3390/curroncol31080340.

Pełny tekst źródła

Streszczenie:

Background: Differences in radiation-induced lymphopenia and prognosis between methods of radiotherapy (RT) for brain metastases remain unclear. Methods: In this retrospective analysis of patients who underwent whole-brain radiotherapy (WBRT) or stereotactic radiosurgery/radiotherapy (SRS/SRT) for brain metastases, baseline total lymphocyte count (TLC) data were obtained within 2 weeks before RT initiation. Follow-up TLC data were evaluated at 0–2, 2–4, and 4–8 weeks after RT completion. Persistent lymphopenia was defined as <800/μL at any time point. Results: Overall, 138 RT courses in 128 patients were eligible (94 WBRT; 44 SRS/SRT). In the WBRT courses, the median baseline TLC was 1325/μL (IQR: 923–1799). Follow-up TLC decreased significantly to 946/μL (626–1316), 992/μL (675–1291), and 1075/μL (762–1435) (p < 0.001). SRS/SRT courses showed no significant TLC decrease. Multivariate analysis revealed female sex, prior RT, baseline TLC < 800/μL, and WBRT use were significantly associated with persistent lymphopenia. In the WBRT group, overall survival was significantly different between those with and without persistent lymphopenia (median, 2.6 and 6.1 months; p < 0.001). However, there was no significant difference in survival in the SRS/SRT group (p = 0.60). Conclusion: This study suggests SRS/SRT might be preferable for lymphocyte preservation in brain metastasis patients.

Style APA, Harvard, Vancouver, ISO itp.

Gomis Selles, E., Ó. Muñoz Muñoz, B. D. Delgado León, P. Cabrera Roldán, A. M. Burgueño Caballero i J. L. López Guerra. "PO-1569 Radiation-induced lymphopenia in pediatric high-risk neuroblastoma". Radiotherapy and Oncology 182 (maj 2023): S1273—S1274. http://dx.doi.org/10.1016/s0167-8140(23)66484-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Więcej źródeł

Rozprawy doktorskie na temat "Radiation-induced lymphopenia"

Pham, Thao Nguyen. "Biοmathematical insights intο radiatiοn-induced systemic immune effects in brain and head & neck cancer using preclinical and clinical mοdels". Electronic Thesis or Diss., Normandie, 2024. http://www.theses.fr/2024NORMC407.

Pełny tekst źródła

Streszczenie:

La radiothérapie, bien qu'efficace contre les tumeurs, peut perturber le système immunitaire et provoquer une lymphopénie, ce qui impacte négativement les résultats du traitement. Des radiothérapies plus ciblées, telles que la protonthérapie, offrent des perspectives prometteuses pour réduire la lymphopénie. Au-delà de la lymphopénie, les sous-populations de leucocytes dans les lignées lymphoïde et myéloïde ont un impact significatif sur la réponse immunitaire antitumorale. Cette thèse examine l'impact de l'irradiation cérébrale sur le système immunitaire en utilisant la modélisation biomathématique. Des données provenant de diverses sources, y compris des essais cliniques, des études animales et des études in vitro sont utilisées pour construire le modèle. L'analyse de la littérature montre un lien quantitatif entre une diminution du nombre de lymphocytes et une survie réduite des patients. De plus, un nouveau modèle de radiosensibilité (modèle de saturation) des lymphocytes est proposé, prouvant une précision supérieure aux modèles linéaires-quadratiques existants. Les études comparant la radiothérapie par rayons X et la protonthérapie chez les souris ont révélé que les rayons X réduisent significativement le nombre de lymphocytes de plusieurs sous-populations et induit une inflammation persistante. La protonthérapie, en revanche, a un impact minimal sur les sous-populations de lymphocytes grâce à son effet balistique épargnant, entre autres, les ganglions lymphatiques cervicaux. La modélisation a également montré que bien que les lymphocytes B et T puissent se rétablir après une déplétion induite par les rayons X, les tumeurs peuvent retarder de manière significative la récupération des cellules B. En outre, les tumeurs affaiblissent elles-mêmes le système immunitaire en diminuant les lymphocytes T circulants. Les données de l'essai clinique CYRAD suggèrent que des doses élevées de radiation aux ganglions lymphatiques lors du traitement du cancer de la tête et du cou affectent de manière significative le nombre de lymphocytes circulants, indépendamment de la dose reçue par le sang lui-même. Ces résultats soulignent l'importance de prendre en compte l'irradiation à la fois du sang mais aussi des ganglions lymphatiques pour préserver le système immunitaire pendant la radiothérapie
Radiotherapy, while effective against tumors, can disturb the immune system and cause lymphopenia, which negatively impacts patient outcomes. Beyond lymphopenia, leukocyte subpopulations of lymphoid and myeloid lineages also have a significant impact on antitumor immune response. More targeted radiation therapies like proton therapy offer promise in reducing lymphopenia. We investigated the impact of brain irradiation on the immune system using biomathematical modeling. Data from various published sources, i.e., clinical trials in humans, animal studies and in vitro data, were used to build the models. A quantitative link between low lymphocyte count and poor patient survival was confirmed using the linear-quadratic model. Modelling accuracy was improved by integrating saturation effects on lymphocyte radiosensitivity (as conceptualized by a new “saturation model” of our own). Modeling based on mice data showed that X-ray therapy significantly reduced lymphocyte counts of multiple subpopulations and induced persistent inflammation while proton therapy had minimal impact on lymphocyte subpopulations, mostly by its ballistic sparing of cervical lymph nodes. Non-linear mixed-effect modeling also showed that while both B and T-lymphocytes recovered after X-ray-induced depletion, tumors could significantly delay B-cell recovery and reduce circulating T cell counts in mice. Additionally, data from a clinical trial in humans suggested that therapeutic radiation doses to lymph nodes significantly affected circulating lymphocyte counts, regardless of the dose to the blood. These findings highlight the importance of considering blood but also lymph node irradiation for preserving the circulating immune cells during and after radiotherapy

Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Radiation-induced lymphopenia"

Rejeb, Mouna Ben, Ines Mlayah, Haifa Rachdi, Dorra Khemir, Rim Moujahed, Lilia Ghorbal i Lotfi Kochbati. "1224 Radiation induced lymphopenia in patients with breast cancer: how can we reduce the risk?" W ESGO 2024 Congress Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/ijgc-2024-esgo.1093.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Sharma, Amrish, Shinya Neri, Bhanu P. Venkatesulu i Steven H. Lin. "Abstract 473: Preclinical model of radiation induced lymphopenia to identify abrogation strategies to enhance cancer therapy". W Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-473.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Hofer, T., AE Nieto, L. Kaesmann, CJ Pelikan, J. Taugner, S. Mathur, C. Eze, C. Belka, F. Manappov i E. Noessner. "P04.01 Early recovery of radiation induced lymphopenia in NSCLC stage III lung cancer: correlation with prognosis in a prospective study". W iTOC10 - 10th Immunotherapy of Cancer Conference, March 21 – 23, 2024 – Munich, Germany. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-itoc10.36.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!